SAN DIEGO, June 14, 2018 /PRNewswire/ — Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the United States, announced today that the company applauds the Drug Enforcement Administration (DEA) for its recent statement on the legality of cannabidiol (CBD) — which further clarifies that some CBD products, such as hemp-derived CBD products sold by Medical Marijuana, Inc., are legal to distribute freely throughout the United States and do not fall under the regulations of the Controlled Substances Act (CSA).
The statement clarified:
“Products and materials that are made from the cannabis plant and which fall outside the CSA definition of marijuana (such as sterilized seeds, oil or cake made from the seeds, and mature stalks) are not controlled under the CSA. Such products may accordingly be sold and otherwise distributed throughout the United States without restriction under the CSA or its implementing regulations.”
The statement continued, “The mere presence of cannabinoids is not itself dispositive as to whether a substance is within the scope of the CSA; the dispositive question is whether the substance falls within the CSA definition of marijuana.”
Medical Marijuana, Inc. sells hemp-derived CBD products through its distribution subsidiaries HempMeds®, Kannaway® and Phyto Animal Health. These products range from tinctures and liquids to topicals and edibles. The company was the first company to ever bring hemp-based CBD oil products to market in the U.S. in 2012 and the first to receive federal government import approvals in Mexico, Paraguay and Brazil.
“This is great news for the cannabis industry, especially for those who are complying with the decision made by the Ninth Circuit Court of Appeals,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “We urge Congress to pass the 2018 Farm Bill, which would permanently remove hemp and hemp